GIC 102
Alternative Names: GIC-102Latest Information Update: 06 Sep 2024
At a glance
- Originator GICELL
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Haematological malignancies
- Phase I Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 06 Sep 2024 Phase-II clinical trials in Haematological malignancies (Combination therapy) in South Korea (Parenteral) (GICELL pipeline, September 2024)
- 31 May 2024 Preclinical trials in Haematological malignancies (Combination therapy) in South Korea (Parenteral) prior to May 2024
- 31 May 2024 Preclinical trials in Solid tumours (Combination therapy) in South Korea (Parenteral) prior to May 2024